<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94208">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02044055</url>
  </required_header>
  <id_info>
    <org_study_id>Liver004</org_study_id>
    <nct_id>NCT02044055</nct_id>
  </id_info>
  <brief_title>Mother-to-child Hepatitis D Transmission</brief_title>
  <official_title>Hepatitis D Virus (HDV) Mother-To-Child Transmission (MTCT) From Hepatitis B Virus (HBV)-Hepatitis D Virus (HDV) Co-infected Pregnant Women: a Retrospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Lariboisière</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HBV can be transmitted from mother-to-child, with a risk increasing according to maternal
      HBV DNA during pregnancy. HDV is a defective virus using HBs Ag for its own replication.
      Nucleosides analogues have only a minor impact on quantitative HBs Ag level. Data about
      vertical HDV transmission are old, justifying a new study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B Virus (HBV) can be transmitted from mother-to-child, with a risk increasing
      according to maternal HBV DNA viral load during the last trimester of pregnancy. Nucleosides
      analogues, lamivudine, telbivudine, or nucleotides analogues, tenofovir DF decrease HBV
      mother-to-child transmission risk, and are recommended in Guidelines (EASL 2012) for
      pregnant women with HBV DNA above 1,000 000 I.U/mL. HDV is a defective virus using HBs Ag
      for its own replication. HDV-HBV co-infection is a re-emerging infectious disease in western
      countries, due to immigration of people coming from endemic areas. Nucleosides analogues
      have only a minor impact on quantitative HBs Ag level (Boyd A et al. AIDS Research and Human
      Retroviruses 2013). Data about vertical HDV transmission are old (Rizzetto, et al. J Med
      Virol 1982), before a large use of nucleosides/nucleotides analogues in HBV infected
      pregnant women, justifying a new study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Hepatitis D antibodies (Ab) in children</measure>
    <time_frame>up to 10 years (expected average: 5 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibodies (Ab) against Hepatitis D Virus (HDV)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDV RNA in children with positive HDV Ab</measure>
    <time_frame>up to 10 years (expected average: 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis D</condition>
  <condition>Transmission</condition>
  <arm_group>
    <arm_group_label>Children born to HBV-HDV women</arm_group_label>
    <description>Children born to HBV-HDV co-infected women will be checked for:
HDV antibodies
if positive, HDV RNA</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All children born in the Maternity Department, Lariboisiere Hospital, from HBV-HDV
        co-infected women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children born in the Maternity Department, Lariboisiere Hospital,

          -  from HBV-HDV co-infected women

          -  with a positive HDV RNA during pregnancy in the pregnant woman

        Exclusion Criteria:

          -  negative HDV RNA during pregnancy in the pregnant woman
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre O SELLIER, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Lariboisiere</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre O SELLIER, M.D., Ph.D</last_name>
    <phone>00 33 149956339</phone>
    <email>pierre.sellier@lrb.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre O SELLIER, M.D., Ph.D</last_name>
      <phone>00 33 149956339</phone>
      <email>pierre.sellier@lrb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre O SELLIER, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>January 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital Lariboisière</investigator_affiliation>
    <investigator_full_name>Stephane Mouly, MD PhD</investigator_full_name>
    <investigator_title>Professor at University Paris VII Denis Diderot, physician</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
